AstraZeneca PLC ADR closed $7.15 short of its 52-week high ($87.68), which the company reached on August 30th.

London-listed AstraZeneca shares fell more than 5% on Tuesday after results from the company's lung cancer trials showed that ...

London-listed shares of AstraZeneca fell on Tuesday after results from the company's lung cancer trials showed that its ...

Detailed results from one of AstraZeneca's key lung cancer trials released on Monday showed that its experimental precision ...

Shares in AstraZeneca dropped nearly 5 per cent on Tuesday after its failure to hit a target in trials for a next-generation ...

A former AstraZeneca Pharmaceuticals LP sales worker adequately alleged she was fired after the company rejected her request ...

Bernstein analyst Justin Smith has maintained their bullish stance on AZN stock, giving a Buy rating yesterday. Justin Smith has given his Buy ...

When AstraZeneca’s Alexion picked up rare disease specialist Syntimmune in 2018 for $ | A Delaware judge agreed that ...

Curating today’s top interviews from around Bloomberg News. Hear conversations with the biggest names in finance, politics ...

AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has failed to improve overall survival (OS) in ...

AstraZeneca (AZN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Eric Le ...

AstraZeneca PLC ADR closed $6.79 below its 52-week high ($87.68), which the company reached on August 30th.